198 related articles for article (PubMed ID: 34815099)
1. Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy.
Dai Z; Wang Q; Tang J; Wu M; Li H; Yang Y; Zhen X; Yu C
Biomaterials; 2022 Jan; 280():121261. PubMed ID: 34815099
[TBL] [Abstract][Full Text] [Related]
2. Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer.
Liu H; Xu C; Meng M; Li S; Sheng S; Zhang S; Ni W; Tian H; Wang Q
Acta Biomater; 2022 May; 144():132-141. PubMed ID: 35307591
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib delivery using a Gd/Fe bimetallic MOF: Enhancing antitumor immunity following microwave-based thermal therapy.
Wang Q; Zhu X; Meng X; Zhong H
Acta Biomater; 2023 Dec; 172():382-394. PubMed ID: 37797707
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
5. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
6. Acidic microenvironment responsive polymeric MOF-based nanoparticles induce immunogenic cell death for combined cancer therapy.
Zhang X; Lu Y; Jia D; Qiu W; Ma X; Zhang X; Xu Z; Wen F
J Nanobiotechnology; 2021 Dec; 19(1):455. PubMed ID: 34963499
[TBL] [Abstract][Full Text] [Related]
7. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
8. Rational design of ICD-inducing nanoparticles for cancer immunotherapy.
Zhang Z; Pan Z; Li Q; Huang Q; Shi L; Liu Y
Sci Adv; 2024 Feb; 10(6):eadk0716. PubMed ID: 38324678
[TBL] [Abstract][Full Text] [Related]
9. A Lactate-Depleting metal organic framework-based nanocatalyst reinforces intratumoral T cell response to boost anti-PD1 immunotherapy.
Zhou J; Hu Y; Cao Y; Ding S; Zeng L; Zhang Y; Cao M; Duan G; Zhang X; Bian XW; Tian G
J Colloid Interface Sci; 2024 Apr; 660():869-884. PubMed ID: 38277843
[TBL] [Abstract][Full Text] [Related]
10. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
11. Photothermal-Chemotherapy Enhancing Tumor Immunotherapy by Multifunctional Metal-Organic Framework Based Drug Delivery System.
Ni W; Wu J; Fang H; Feng Y; Hu Y; Lin L; Chen J; Chen F; Tian H
Nano Lett; 2021 Sep; 21(18):7796-7805. PubMed ID: 34516141
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
13. Metal-Organic Framework-Based Nano-Activators Facilitating Microwave Combined Therapy via a Divide-and-Conquer Tactic for Triple-Negative Breast Cancer.
Wu Q; Tan L; Ren X; Fu C; Chen Z; Ren J; Ma T; Meng X
ACS Nano; 2023 Dec; 17(24):25575-25590. PubMed ID: 38095158
[TBL] [Abstract][Full Text] [Related]
14. A Biomimetic Metal-Organic Framework Nanosystem Modulates Immunosuppressive Tumor Microenvironment Metabolism to Amplify Immunotherapy.
Wang H; Wu C; Tong X; Chen S
J Control Release; 2023 Jan; 353():727-737. PubMed ID: 36473607
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal-Organic Framework Nanoparticles to Boost Cancer Immunotherapy.
Cai Z; Xin F; Wei Z; Wu M; Lin X; Du X; Chen G; Zhang D; Zhang Z; Liu X; Yao C
Adv Healthc Mater; 2020 Jan; 9(1):e1900996. PubMed ID: 31746153
[TBL] [Abstract][Full Text] [Related]
16. Catalytically Active Metal-Organic Frameworks Elicit Robust Immune Response to Combination Chemodynamic and Checkpoint Blockade Immunotherapy.
Wang X; Luo J; Wang J; Cao J; Hong Y; Wen Q; Zeng Y; Shi Z; Ma G; Zhang T; Huang P
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6442-6455. PubMed ID: 36700645
[TBL] [Abstract][Full Text] [Related]
17. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
[TBL] [Abstract][Full Text] [Related]
18. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
19. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
Zhang S; Huang Y; Pi S; Chen H; Ye F; Wu C; Li L; Ye Q; Lin Y; Su Z
J Nanobiotechnology; 2023 Oct; 21(1):360. PubMed ID: 37789342
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety.
Zhang J; Li W; Qi Y; Wang G; Li L; Jin Z; Tian J; Du Y
Angew Chem Int Ed Engl; 2023 Jan; 62(5):e202214750. PubMed ID: 36458940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
